/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that...

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

OliX eases overhang, targets Q4 tech transfer as Lilly ties deepen Lockup expiry shifts focus to Q4 deal prospects, Lilly options, and pipeline milestones

In the most recent trading session, Eli Lilly (LLY) closed at $1, indicating a -2.33% shift from the previous trading day.

View the basic LLY option chain and compare options of Eli Lilly and Company on Yahoo Finance.

Some lost nearly a quarter of their body weight over 80 weeks using 'triple agonist' medication

Las acciones de Eli Lilly cotizaban a 1.038,60 euros fuera de horario a las 19:46 horas. CEST el 30 de septiembre de 2026, 0,23 p menos

Eli Lilly (NYSE:LLY) shows new Foundayo data versus oral semaglutide at EASD. See obesity drug and healthcare sector context.

Eli Lilly reported EBGLYSS Phase 3b results showing improved hand-and-foot atopic dermatitis outcomes and submitted data for review.

Eli Lilly and Company said Wednesday its experimental EloraTZP combination produced greater weight loss than tirzepatide alone in a mid-stage trial involving 367 adults with obesity or overweight and ...

Eli Lilly (NYSE:LLY) is in focus as fresh retatrutide data extends the obesity-and-diabetes pipeline debate. See the September 30 setup, key risks, sector con

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.